Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix or Prevenar-13.
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PIEN
- 25 Apr 2017 Results (n=890) assessing differences in immune responses to PCV13 and PCV10 using patient data from NCT01204658, NCT01616459 and NTR3069 trials, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 17 Aug 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2011-002103-15).
- 17 Aug 2013 Status changed from planning to completed as reported by European Clinical Trials Database.